Business Wire

Applied DNA Signs Definitive Agreements with Colorcon for Molecular Tagging in the Pharmaceutical and Nutraceutical Markets

Del

Applied DNA Sciences, Inc., (NASDAQ: APDN) (“Applied DNA” or the “Company,”) has signed a License and Cooperation Agreement and a related Supply Agreement (collectively known as the “Agreements”), effective March 31, 2018, with Colorcon, Inc. (“Colorcon”) for the use of Applied DNA’s SigNature® molecular tags in Colorcon’s product offerings and access to the Company’s associated authentication technologies. These Agreements follow the memorandum of understanding (MOU) announced on December 18, 2017.

Under the terms of the Agreements, Applied DNA grants Colorcon exclusive worldwide right to use the Company’s molecular tags and associated authentication technologies in film coatings for solid oral dosage form (“SOD”) applications, for which Colorcon is the largest global supplier, and non-exclusive rights to use the Company’s technologies in inks and colorants for SOD applications. Pursuant to the Agreements, Applied DNA will supply taggant and authentication materials to Colorcon in exchange for long-term royalties on the sale of Colorcon products incorporating the Company’s molecular tags and on the sale of authentication services related thereto. Further, the first of two milestone payments is payable to Applied DNA with the signing of the Agreements. The Company will receive the second milestone payment upon initial approval by a regulatory authority for application in a SOD pharmaceutical or nutraceutical product application. The Agreements generally expire on the later of October 1, 2032 or the last expiration date of any patent licensed pursuant to the Agreements.

“With the signing of these definitive agreements and Colorcon’s industry-leading role, we demonstrate our continuing ability to monetize our DNA molecular taggant platform and associated services to drive revenue growth. The seamless solution integrating our molecular tag with Colorcon's film coatings puts us on a path to adoption by Colorcon’s current and prospective pharmaceutical customers,” stated Dr. James Hayward, President and CEO of Applied DNA. Dr. Hayward added that: “Molecular tags will provide traceability for audits and law enforcement and, perhaps most importantly, forensic confirmation of the authenticity of the drug product to the patient and all those in the supply chain, including the pharmacist, the drug distributors and manufacturers. We are gratified to be working with a world leader whose sales channel greatly amplifies our combined access to the market.”

“Our teams are already actively engaged in discussions with potential customers,” stated Kelly Boyer, General Manager Film Coatings Business Unit for Colorcon, Inc.

Ms. Boyer continued, “Colorcon has an established reputation for innovation and service. Applied DNA’s SigNature molecular tags and authentication technologies provide value-addition at a time when regulators are demanding that the industry implement serialization in order to track packaging. The collaboration goes a significant step further by enabling traceability at the level of single unit, solid oral doses, and it is complementary to the provisions of the Drug Supply Chain Security Act.”

Colorcon has team members with extensive experience in global regulatory compliance, while Applied DNA has the benefit of several of its management team with experience in the pharmaceutical industry, and the Company has already scaled to supply large, global commercial ecosystems. Applied DNA’s Molecular Tags have been included in over 200 million pounds of cotton, over 15 million pounds of synthetic fibers, and over 800,000 microcircuits for the Department of Defense. The Company’s data portals, supporting hundreds of thousands of data transactions per day, have stored over 300,000 sample testing reports, and are now exchanging data with multiple third-party platforms.

About Colorcon®

Colorcon is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Colorcon’s best-in-class products and technologies are complemented by Colorcon’s extensive application data and value-added services to support all phases of solid oral dose design and development. Colorcon’s focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on the superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics, personalized medicine and therapeutics.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based "CertainT®" platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopiable, security and authentication solutions, targeted a wide range of industries, including but not limited to, pharmaceuticals and nutraceuticals, textiles and defense materials , BackTrac® and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. Our products provide a forensic chain of evidence in large commercial ecosystems

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our lack of significant revenues, limited financial resources, limited market acceptance, history of net losses, market competition, risk of not obtaining regulatory approval and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly report on Form 10-Q filed on February 8, 2018, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contact information

Investors:
LHA Investor Relations
Sanjay M. Hurry, 212-838-3777
shurry@lhai.com
or
Media:
DGI Comm
Cheryl Schneider, 212-825-3210
cschneider@dgicomm.com
or
Program:
Applied DNA Sciences, Inc.
James A. Hayward, 631-240-8800
Chief Executive Officer
james.hayward@adnas.com
web:  www.adnas.com
twitter: @APDN

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Jetex Now the Exclusive Dealer in the Middle East for Hi-Tech New HondaJet10.12.2018 09:52Pressemelding

Jetex is bringing the next-generation in advanced private jets to the Middle East after striking an agreement with Honda Aircraft Company to become the exclusive authorized dealer for the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005273/en/ Adel Mardini of Jetex signs with Simon Roads of Honda Aircraft Company (Photo: AETOSWire) The deal means Jetex is now the manufacturer’s sole representative for the new HondaJet offering sales and support across the Gulf and Middle East region. “With Honda’s brand strength and recognition in the Middle East, we have received tremendous interest in the HondaJet Elite. We are proud to appoint Jetex as HondaJet Middle East to provide our customers with a committed sales team in the region for the world’s most advanced very light jet,” said Honda Aircraft President and CEO Michimasa Fujino. “We are proud to be chosen by Honda Aircraft Company and excited to be awarded the r

China Shanghu Builds Itself into an International Health Demonstration Zone10.12.2018 09:16Pressemelding

On October 25, 2018, the 13th Meeting of the Conference of the Contracting Parties to the Ramsar Convention on Wetlands declared that Changshu was put on the list of the first “International Wetland Cities” in the world, in recognition of its success in the protection of wetland ecology. The award is arguably the most influential on a global scale—supreme and unchallenged. It was against this backdrop that the project of Changshu Shanghu International Health Demonstration Zone was commenced. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005254/en/ 2025 Shanghu International Health Demonstration Zone (Photo: Business Wire) Covering an area of about 40 million square meters, Changshu Shanghu, a national wetland park, is slap bang in the middle of the city, including 800-hectare ecological lake, four parks and ten places of interest. In compliance with the strategy for Healthy China 2030, the characteristic “Modern Healt

KOKUYO's "360° Gliding Chair ing" Wins FRAME Awards ORGATEC 2018 in Two Categories10.12.2018 09:00Pressemelding

KOKUYO Co., Ltd. (TOKYO:7984), a leading provider of office design and furniture in Japan, won FRAME Awards for "360º Gliding Chair ing" in two categories at ORGATEC 2018, “Trade Fair Stand of the Year” and “Best Use of Light,” which is organized by the Dutch interior design magazine "FRAME." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005248/en/ KOKUYO's "360° Gliding Chair ing" Wins FRAME Awards ORGATEC 2018 (Photo: Business Wire) ORGATEC 2018, the largest International Trade Fair for Furnishing and Management of Offices and Office Facilities was held from October 23 to 27 in Cologne, Germany. Internationally renowned creators and critics from Amsterdam, Berlin, and elsewhere in Europe were the judges of FRAME Awards critiquing global furniture manufacturer booths in four categories: Best Use of Colour, Best Use of Light, Best Use of Material, and Trade Fair Stand of the Year. Winners in these categories will be h

SIAE MICROELETTRONICA Outperforms Telefónica 10Gbps E-band Tests to Power 5G Backhauling10.12.2018 08:00Pressemelding

Telefónica a global leader mobile operator and SIAE MICROELETTRONICA a leader in wireless transport technology have put to the test the high capacity 10Gbps wireless links to enhance the backhauling network for the future advent of 5G. The millimetre-wave point-to-point radio operating at 80GHz E band carrier, offers the lowest transport latency and the highest wireless capacity of 10Gbps over a single channel, satisfying the strict 5G requirements. Telefónica successfully field tested SIAE MICROELETTRONICA millimetre-wave radio solution in two use cases: 10Gbps point-to-point links addressing urban applications and the multicarrier link aggregation addressing the sub-urban applications, pushing high capacity connectivity to longer distances. “SIAE MICROELETTRONICA and Telefónica have cooperated over multiple projects all aiming to satisfy the 5G backhaul requirements. From microwave SDN applications to the introduction of state of the art millimetre-wave radio, once again crossing tog

Fishawack Acquires Creative Consultancy Blue Latitude Health10.12.2018 07:00Pressemelding

The Fishawack Group of Companies, one of the world’s largest independent medical communications and medical marketing organizations, has acquired Blue Latitude Health, based in London, UK, and New York, USA. Blue Latitude Health is a creative consultancy combining the commercial focus of a consultancy with the creative vision of an agency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181209005023/en/ Dominic Miller, Fred Bassett, Oliver Dennis (back row from left to right), Martin Brass, Gail Flockhart (front row from left to right). (Photo: Business Wire) “In 2016, we set out our vision to form a major new force in the global creative agency space that would make us as strong in the creative arena as we already are in medical communications,” explained Oliver Dennis , Chief Executive Officer of the Fishawack Group. “With three acquisitions in this space in the last 16 months, I think we’ve firmly announced our intention t

Gilead Sciences Names Daniel O’Day Chairman and Chief Executive Officer10.12.2018 06:00Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel O’Day Chairman of the Board and Chief Executive Officer, effective March 1, 2019. Mr. O’Day is currently the CEO of Roche Pharmaceuticals. He has held the position since 2012, and prior to that led Roche Diagnostics. His career spans three decades of diverse leadership roles across North America, Asia Pacific and Europe. The Board has also appointed Gregg Alton as interim Chief Executive Officer for the period of January 1, 2019 until Mr. O’Day’s start date of March 1, 2019. Mr. Alton has held a number of executive positions at Gilead over the past 20 years, with experience in legal, medical affairs, policy and commercial. He previously served as general counsel and in August of this year, was appointed Chief Patient Officer. “Following a comprehensive search, the Board became convinced that Dan is the right leader to bring Gilead into the future,” said John C. Martin, PhD, Chairman, Gilea